Journal: EMBO Molecular Medicine

Article Title: PlexinD1 is a driver and a therapeutic target in advanced prostate cancer

doi: 10.1038/s44321-024-00186-z

Figure Lengend Snippet: Reagents and tools table

Article Snippet: p-ErbB2 (Tyr1221/1222) (WB: 1/1000; IHC: 1/400) , Cell Signaling Technology , 2243.

Techniques: Recombinant, Sequencing, Control, Transfection, Membrane, Reverse Transcription, Software, Microarray, Subcloning, shRNA, Cell Viability Assay, Viability Assay, Reporter Assay, In Situ, Enzyme-linked Immunosorbent Assay, Phospho-proteomics, Extraction, Bicinchoninic Acid Protein Assay, Magnetic Beads, Gel Extraction, Purification, Ligation, Mutagenesis, Chromatin Immunoprecipitation

Journal: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research

Article Title: Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo

doi: 10.12659/MSM.909865

Figure Lengend Snippet: Radiation treatment increased the levels of phosphorylated epidermal growth factor receptor (p-EGFR), phosphorylated AKT (p-AKT), and phosphorylated HER-2 (p-HER2) at low and high doses in mouse bladder tumor line-2 (MBT-2) cells in a time-dependent manner. MBT-2 cells were exposed to radiation doses ranging from 2.5–10 Gy, followed by preparation of cell lysates. Western blot analysis shows a time-dependent increase in phosphorylated epidermal growth factor receptor (p-EGFR), phosphorylated AKT (p-AKT), and phosphorylated HER-2 (p-HER2).

Article Snippet: The primary antibodies to EGFR, phosphorylated EGFR (p-EGFR), HER-2, and phosphorylated HER-2 (p-HER-2) were obtained from Abcam (Cambridge, MA, USA).

Techniques: Western Blot

Journal: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research

Article Title: Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo

doi: 10.12659/MSM.909865

Figure Lengend Snippet: Lapatinib treatment down-regulated the radiation-mediated levels of phosphorylated epidermal growth factor receptor (p-EGFR), phosphorylated AKT (p-AKT), and phosphorylated HER-2 (p-HER2) in mouse bladder tumor line-2 (MBT-2) cells in a dose-dependent manner. Pretreatment of mouse bladder tumor line-2 (MBT-2) cells with lapatinib (100 nM and 200 nM) for 24 h followed by radiation of varying doses range from 2.5–10 Gy. The cell lysates were obtained after 2 h. Western blots were performed for phosphorylated epidermal growth factor receptor (p-EGFR), phosphorylated AKT (p-AKT), and phosphorylated HER-2 (p-HER2). β-actin was used as loading control. Lapatinib treatment down-regulated the radiation-mediated levels of p-EGFR, p-AKT, p-HER2 in MBT-2 cells in a dose-dependent manner.

Article Snippet: The primary antibodies to EGFR, phosphorylated EGFR (p-EGFR), HER-2, and phosphorylated HER-2 (p-HER-2) were obtained from Abcam (Cambridge, MA, USA).

Techniques: Western Blot

Journal: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research

Article Title: Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo

doi: 10.12659/MSM.909865

Figure Lengend Snippet: Lapatinib treatment combined with radiation resulted in an increased tumor suppressive effect in the mouse bladder tumor line-2 (MBT-2) xenografts. ( A ) The mouse tumor xenograft model was created by injecting MBT-2 cells subcutaneously in C3H/HeN mice and were divided into four groups, treated with lapatinib (200 mg/kg), radiation (15 Gy), and a combination of both, and with vehicle (control). Values are shown as mean tumor volumes per group. ( B ) The mice with tumors were sacrificed on the 8 th day. Photomicrographs of sections of the tumor tissues, treated with radiation, lapatinib, and combined radiation and lapatinib were recorded ×200 magnification, following immunohistochemical staining with primary antibodies for HER-2 and EGFR ( A1–H1 ).

Article Snippet: The primary antibodies to EGFR, phosphorylated EGFR (p-EGFR), HER-2, and phosphorylated HER-2 (p-HER-2) were obtained from Abcam (Cambridge, MA, USA).

Techniques: Immunohistochemical staining, Staining